Evaluation of antidepressant activity of tramadol in mice: an experimental study

Ubale, Vishal M.; Jaju, Jugalkishore B.; Gosavi, Punam A.; Pawar, Ganesh; Dharmadhikari, Shrikant C.; Parekar, Sonal M.

doi:10.18203/2319-2003.ijbcp20150017

Cited by 4 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present findings in the open field test are similar to those reported by Szkutnik-Fiedler et al (2012) and Ubale et al (2015). Although previous research showed inhibited locomotor activity after acute (Alemán-Laporte et al, 2022) or chronic tramadol administration to rats (Elsukary et al, 2022) in contrast to our observation of unaffected activity, it may be explained by the discrepancy of open The level of DA is known to be reduced after naloxone-induced withdrawal (Rada et al, 2004), which was observed in the present study.…”

Section: Figsupporting

confidence: 87%

See 1 more Smart Citation

A novel tramadol–polycaprolactone implant could palliate heroin conditioned place preference and withdrawal in rats: behavioral and neurochemical study

Elshebiney,

Elgohary,

El-Shamarka

et al. 2024

Behavioural Pharmacology

View full text Add to dashboard Cite

Drug dependence is a chronic brain disease characterized by craving and recurrent episodes of relapse. Tramadol HCl is a promising agent for withdrawal symptoms management, considering its relatively low abuse potential and safety. Oral administration, however, is not preferred in abstinence maintenance programs. Introducing an implantable, long-lasting formula is suggested to help outpatient abstinence programs achieve higher rates of treatment continuation. Tramadol implants (T350 and T650) were prepared on polycaprolactone polymer ribbons by the wet method. Male Wistar rats were adapted to heroin-conditioned place preference (CPP) at escalating doses (3–30 mg/kg, intraperitoneally, for 14 days). Implants were surgically implanted in the back skin of rats. After 14 days, the CPP score was recorded. Naloxone (1 mg/kg, intraperitoneally) was used to induce withdrawal on day 15, and symptoms were scored. Elevated plus maze and open field tests were performed for anxiety-related symptoms. Striata were analyzed for neurochemical changes reflected in dopamine, 3,4-dihydroxyphenyl acetic acid, gamma-aminobutyric acid, and serotonin levels. Brain oxidative changes including glutathione and lipid peroxides were assessed. The tramadol implants (T350 and T650) reduced heroin CPP and limited naloxone-induced withdrawal symptoms. The striata showed increased levels of 3,4-dihydroxyphenyl acetic acid, and serotonin and decreased levels of gamma-aminobutyric acid and dopamine after heroin withdrawal induction, which were reversed after implanting T350 and T650. Implants restore the brain oxidative state. Nonsignificant low naloxone-induced withdrawal score after the implant was used in naive subjects indicating low abuse potential of the implants. The presented tramadol implants were effective at diminishing heroin CPP and withdrawal in rats, suggesting further investigations for application in the management of opioid withdrawal.

show abstract

Section: Figsupporting

confidence: 87%

“…The present findings in the open field test are similar to those reported by Szkutnik-Fiedler et al . (2012) and Ubale et al . (2015).…”

Section: Discussionmentioning

confidence: 95%

A novel tramadol–polycaprolactone implant could palliate heroin conditioned place preference and withdrawal in rats: behavioral and neurochemical study

Elshebiney,

Elgohary,

El-Shamarka

et al. 2024

Behavioural Pharmacology

View full text Add to dashboard Cite

show abstract

“…The use of tramadol as an antidepressant has not received such scrutiny. Nevertheless, its ability to function as an antidepressant has been well-documented. − …”

Section: Methodsmentioning

confidence: 99%

“…In addition to its use as an analgesic, there is substantial evidence that tramadol is an effective antidepressant. This evidence is presented and/or summarized in over 50 citations in the peer-reviewed biomedical literature in animal models, − in humans, − in the patent literature, − and in reports provided by patients. − The World Health Organization (WHO) Expert Committee on Drug Dependence published a comprehensive review of the chemistry, biochemistry, and biomedical aspects of tramadol in 2018 . Much of the background information and review material presented here concerning this medication is from this reference and references therein.…”

mentioning

confidence: 99%

Low-Dose Tramadol as an Off-Label Antidepressant: A Data Mining Analysis from the Patients’ Perspective

Bumpus

2020

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

The purpose of this analysis was to assess, from the patients' perspective, the effectiveness and relative safety of tramadol as an off-label antidepressant and to determine if patients' views and experiences are consistent with the biomedical literature. Method: A data mining approach was used to analyze databases available at drugs.com. Results: Tramadol was reported to be an effective or very effective antidepressant by 94.6% of patients (123/130) who provided ratings submitted to User Reviews for Tramadol to Treat Depression (https://www.drugs.com/comments/tramadol/ for-depression.html). When compared to 34 other antidepressants in the database titled Drugs Used to treat Depression (https://www.drugs.com/condition/depression.html), for which there were ≥100 individual reviews for each drug, tramadol was rated as being the most effective (effectiveness rating = 9.1/10). Phenelzine (effectiveness rating = 8.7/10) was the only other antidepressant having ≥100 individual reviews coupled with a very high (8.0−10.0) effectiveness rating. Eleven patients reported significant symptoms of withdrawal upon cessation of tramadol, and five patients reported loss or reduction of libido as a side effect. Most (57/72, 79.2%) patients who reported a dose consumed experienced relief from depression at low therapeutic doses (25−150 mg/day). Fourteen patients reported taking this antidepressant for 5−10 years, and four patients reported taking tramadol for 10 or more years. Results demonstrated that most patients' comments and beliefs are consistent with the biomedical literature. Conclusions: Patients' reviews coupled with a survey of the biomedical literature indicate that at low therapeutic doses in the absence of interactions with other drugs, adult patients found tramadol to be a generally safe, effective, and fast-acting medication for relief from depression.

show abstract

Role of apoptosis and autophagy in mediating tramadol-induced neurodegeneration in the rat hippocampus

et al. 2023

View full text Add to dashboard Cite

BackgroundTramadol (TRA) is a pain killer, which its abuse is widely increased during recent years, but clear mechanism for induction of neurotoxicity remains unclear. The present study aims to investigate involvement of apoptosis and autophagy signaling pathways and also mitochondrial system on TRA induced neurotoxicity. Materials and MethodsSixthy adult male rats were randomly divided into ve groups that received standard saline and TRA in doses of 25, 50, 75, 100 and 150 mg/kg as intraperitoneal administration for 21 days, respectively. In 22th day, Open Field Test (OFT), as standard test for hippocampal cell damages was used. Also hippocampal level of JNK, Bcl-2, Beclin1 and Bax proteins as well as mitochondrial quadruple complex enzymes was measured ResultsTRA at doses 75,100 and 150 mg/kg causes dysfunction in OFT behavioral and also in mentioned high doses could increases level of both activated (total) and non-activated from of JNK and also increased Beclin-1 and Bax. TRA at doses of 75,100 and 150 mg/kg increased phosphorylated form of Bcl-2 level while decreased un-phosphorylated (total form) form of Bcl-2. ConclusionAccording to obtained data, TRA causes activation of apoptosis and or autophagy processes via modulation of TNF-α or IL-1β/JNK/Bcl-2/Beclin1 and Bcl-2/Bax signaling pathway and causes dysfunction of mitochondrial respiratory chain enzymes.

show abstract

Evaluation of antidepressant activity of tramadol in mice: an experimental study

Cited by 4 publications

References 10 publications

A novel tramadol–polycaprolactone implant could palliate heroin conditioned place preference and withdrawal in rats: behavioral and neurochemical study

A novel tramadol–polycaprolactone implant could palliate heroin conditioned place preference and withdrawal in rats: behavioral and neurochemical study

Low-Dose Tramadol as an Off-Label Antidepressant: A Data Mining Analysis from the Patients’ Perspective

Role of apoptosis and autophagy in mediating tramadol-induced neurodegeneration in the rat hippocampus

Contact Info

Product

Resources

About